These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 24070010)

  • 1. Etanercept (Enbrel) in the treatment of juvenile idiopathic arthritis.
    Berard RA; Laxer RM
    Expert Opin Biol Ther; 2013 Nov; 13(11):1623-30. PubMed ID: 24070010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
    Horneff G; Foeldvari I; Minden K; Trauzeddel R; Kümmerle-Deschner JB; Tenbrock K; Ganser G; Huppertz HI
    Arthritis Rheumatol; 2015 May; 67(8):2240-9. PubMed ID: 25891010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
    JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.
    Mourão AF; Santos MJ; Melo Gomes JA; Martins FM; Mendonça SC; Oliveira Ramos F; Fernandes S; Salgado M; Guedes M; Carvalho S; Costa JA; Brito I; Duarte C; Furtado C; Lopes A; Rodrigues A; Sequeira G; Branco JC; Fonseca JE; Canhão H
    Rheumatology (Oxford); 2016 Apr; 55(4):697-703. PubMed ID: 26672905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients.
    Southwood TR; Foster HE; Davidson JE; Hyrich KL; Cotter CB; Wedderburn LR; Hull RG; Venning HE; Rahman JK; Cummins CL;
    Rheumatology (Oxford); 2011 Jan; 50(1):189-95. PubMed ID: 21047801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept.
    Klotsche J; Minden K; Thon A; Ganser G; Urban A; Horneff G
    Arthritis Care Res (Hoboken); 2014 Feb; 66(2):253-62. PubMed ID: 23983081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
    Prince FH; Twilt M; ten Cate R; van Rossum MA; Armbrust W; Hoppenreijs EP; van Santen-Hoeufft M; Koopman-Keemink Y; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2009 May; 68(5):635-41. PubMed ID: 18413443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review.
    Shenoi S; Wallace CA
    Paediatr Drugs; 2010 Dec; 12(6):367-77. PubMed ID: 21028916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis.
    De Sanctis S; Marcovecchio ML; Gaspari S; Del Torto M; Mohn A; Chiarelli F; Breda L
    J Rheumatol; 2013 Jun; 40(6):943-8. PubMed ID: 23547210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept.
    van Dijken TD; Vastert SJ; Gerloni VM; Pontikaki I; Linnemann K; Girschick H; Armbrust W; Minden K; Prince FH; Kokke FT; Nieuwenhuis EE; Horneff G; Wulffraat NM
    J Rheumatol; 2011 Jul; 38(7):1441-6. PubMed ID: 21459936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan.
    Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Higuchi R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
    Mod Rheumatol; 2012 Sep; 22(5):720-6. PubMed ID: 22212889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis].
    Horneff G
    Z Rheumatol; 2010 Aug; 69(6):516-26. PubMed ID: 20532787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept: efficacy and safety for approved indications.
    Kerensky TA; Gottlieb AB; Yaniv S; Au SC
    Expert Opin Drug Saf; 2012 Jan; 11(1):121-39. PubMed ID: 22074366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study.
    Lahdenne P; Vähäsalo P; Honkanen V
    Ann Rheum Dis; 2003 Mar; 62(3):245-7. PubMed ID: 12594111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term quality of life and functional outcome of patients with juvenile idiopathic arthritis in the biologic era: a longitudinal follow-up study in the Dutch Arthritis and Biologicals in Children Register.
    Anink J; Prince FH; Dijkstra M; Otten MH; Twilt M; ten Cate R; Gorter SL; Koopman-Keemink Y; van Rossum MA; Hoppenreijs EP; van Suijlekom-Smit LW
    Rheumatology (Oxford); 2015 Nov; 54(11):1964-9. PubMed ID: 26078219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Juvenile idiopathic arthritis and malignancy.
    Ruperto N; Martini A
    Rheumatology (Oxford); 2014 Jun; 53(6):968-74. PubMed ID: 24185766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience.
    Baszis K; Garbutt J; Toib D; Mao J; King A; White A; French A
    Arthritis Rheum; 2011 Oct; 63(10):3163-8. PubMed ID: 21702011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticular course juvenile idiopathic arthritis: experience from Japanese clinical trials.
    Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Kurosawa R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
    Mod Rheumatol; 2011 Dec; 21(6):572-8. PubMed ID: 21479889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO.
    Minden K; Niewerth M; Zink A; Seipelt E; Foeldvari I; Girschick H; Ganser G; Horneff G
    Rheumatology (Oxford); 2012 Aug; 51(8):1407-15. PubMed ID: 22447885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis.
    Papsdorf V; Horneff G
    Rheumatology (Oxford); 2011 Jan; 50(1):214-21. PubMed ID: 21148155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.